Transplant centers participating in the CIBMTR must submit a Post-TED Form for recipients who meet any of the following criteria:

  • Recipient receives a transplant at a United States center designated as a TED-only center.
  • Recipient receives a transplant at a United States center designated as Comprehensive Report Form center, but has been assigned to the TED track by the Form Selection Algorithm.
  • Recipient receives an allogeneic transplant at a United States center designated as Comprehensive Report Form center, but has not consented to participate in research.
  • Recipient receives a transplant at an international center, has consented to participate in research, and has been assigned to the TED track by the Form Selection Algorithm.

The Post-TED fulfills the requirements of the SCTOD for recipients meeting any of the above criteria. For more information regarding the SCTOD, see General Instructions, Stem Cell Therapeutics Outcomes Database.

For more information, including information on the TED and Comprehensive Report Form Selection Algorithm, see Section 1 in the Center Reference Guide.

The Post-TED must be completed at the following time points: 100 days, six months, and annually post-HCT. These forms should be completed as closely to these time points as possible. The structure of the TED Forms is such that each form should fit on a timeline with distinct start and stop dates that do not overlap any other forms, except in the case of a subsequent HCT.

Subsequent HCT:
If a recipient receives a subsequent HCT between Post-TED time points (100 day, six months, annually), the TED form sequence will start over again with another Pre-TED.

However, if the recipient receives an autologous HCT as a result of a poor graft or graft failure, the TED form sequence will not start over again. Generally this type of infusion (autologous rescue) is used to treat the recipient’s poor graft response, rather than to treat the recipient’s disease.

Contact the CIBMTR Customer Service Center if the subsequent Pre-TED does not come due automatically.

Non-Malignant Diseases
If the HCT being reported was given to treat a non-malignant disease (as reported on the Pre-TED Disease Classification Form {Form 2402}), do not complete the following sections of the Post-TED Form:

  • Q84 – 106: Disease Assessment at the Time of Best Response to HCT
  • Q107 – 111: Post-HCT Therapy
  • Q112 – 122: Relapse or Progression Post-HCT
  • Q123 – 126: Current Disease Status

Lost to Follow-Up:
Occasionally, centers may lose contact with recipients for a variety of reasons, including the recipient’s moving, changing physicians, or death. If contact with a recipient appears lost, please consider calling the recipient at home or work, sending a letter, communicating with the treating or referring physician, or contacting the hospital billing department. If no documentation exists and several unsuccessful attempts have been made to contact the recipient, they are considered lost to follow-up and the form may be marked as such using the Lost to Follow-Up tool in FormsNet3SM for each reporting period in which no contact exists.

Links to Sections in Manual:
Q1 – 6: Survival
Q7 – 13: Subsequent Transplant
Q14 – 16: Initial ANC Recovery
Q17 – 18: Initial Platelet Recovery
Q19 – 44: Graft-Versus-Host Disease
Q45 – 47: Liver Toxicity Prophylaxis
Q48 – 49: Veno-occlusive disease (VOD) / Sinusoidal obstruction syndrome (SOS)
Q50 – 56: Infection
Q57 – 64: New Malignancy, Lymphoproliferative or Myeloproliferative Disorder
Q65 – 83: Chimerism Studies
Q84 – 106: Disease Assessment at the Time of Best Response to HCT
Q107 – 111: Post-HCT Therapy
Q112 – 122: Relapse or Progression Post-HCT
Q123 – 126: Current Disease Status

Manual Updates:
Sections of the Forms Instruction Manual are frequently updated. The most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.

If you need to reference the historical Manual Change History for this form, please click here or reference the retired manual section on the Retired Forms Manuals webpage.

Date Manual Section Add/Remove/Modify Description
5/19/2022 2450: Post-TED Add Reporting ‘No’ for Clinical / Hematologic Assessments blue instruction box added above Q104
5/19/2022 2450: Post-TED Modify Instructions clarified on how to report yes and no for Q104: If the recipient’s best response is Not in Complete Remission, report the latest assessment performed during the reporting period and prior to any treatment for relapsed, progressive, or persistent disease (excluding treatment for minimal residual disease). If testing was not performed prior to the initiation of treatment, report No and go to question 107 Yes If assessments were performed prior to relapse, progression or treatment for persistent disease, (excluding treatment for minimal residual disease). Report No If assessments were not performed prior to relapse, progression or treatment for persistent disease, (excluding treatment for minimal residual disease). If the recipient’ best response is Complete Remission, report testing performed closest to the date of best response (question 87) and within the time windows in the Disease Assessment Time Windows table. If testing was not performed within the applicable time window, report No and go to question 107. Yes if disease assessments were performed within the time windows in the Disease Assessment Time Windows table above. If testing was not performed within the applicable time window, report No
5/19/2022 2450: Post-TED Modify Instructions clarified on how to report the assessment date for Q105: If the best response is Not in complete remission – no disease detected but incomplete evaluation to establish CR, report the date of the most clinical / hematologic recent testing performed during the reporting period and prior to treatment for relapsed, progressive, or persistent disease, if applicable. If no treatment for relapsed, progressive, or persistent disease was given, report the date of the most disease-specific testing performed within approximately 30 days of the follow-up date. last assessment performed in the reporting period and prior to relapse, progression, or treatment for persistent disease, if applicable. If the best response is Not in complete remission – disease detected, report the most recent assessment performed in the reporting period that detects disease and prior to progression or treatment for persistent disease, if applicable. If disease was not detected by this method report the date of the most recent assessment performed and prior to relapse, progression or treatment for persistent disease, if applicable.
5/19/2022 2450: Post-TED Modify Instructions clarified on when to report no and yes for Q101: Report No if radiologic assessments were not performed during the reporting period positive for disease in the past but not performed during the current reporting period.
If the recipient’s best response is Not in Complete Remission, report the latest assessment performed during the reporting period and prior to treatment for relapsed, progressive, or persistent disease (excluding treatment for minimal residual disease). If testing was not performed prior to the initiation of treatment, report No and go to question 104 Yes if assessments were performed, prior to any relapse, progression or treatment for persistent disease, (excluding treatment for minimal residual disease). Report No if assessments were not performed, prior to any relapse, progression, or treatment for persistent disease (excluding treatment for minimal residual disease).
If the recipient’ best response is Complete Remission, report testing performed closest to the date of best response (question 87) and within the time windows in the Disease Assessment Time Windows table. If testing was not performed within the applicable time window, report No and go to question 104. Yes if disease assessments were performed within the time windows in the Disease Assessments Time Windows table above. If testing was not performed within the applicable time window, report No.
5/19/2022 2450: Post-TED Modify Instructions clarified on how to report the assessment date for Q102: If the best response is Complete remission, report the date of the assessment performed nearest the date of best response within the time window and prior to relapse or progression, if applicable. If the best response is Not in complete remission – no disease detected but incomplete evaluation to establish CR, report the date of the most recent radiological testing performed during the reporting period and prior to treatment for relapsed, progressive, or persistent disease, if applicable. If no treatment for relapsed, progressive, or persistent disease was given, report the date of the most recent radiological assessment performed within approximately 30 days of the follow-up date last assessment performed in the reporting period and prior to relapse, progression, or treatment for persistent disease, if applicable. If the best response is Not in complete remission – disease detected, report the most recent radiologic testing performed in the reporting period that detects disease *and prior to progression or treatment for persistent disease, if applicable. If disease was not detected by this method, report the date of the most recent radiological testing performed and prior to relapse, progression, or treatment for persistent disease, if applicable.. Report the date of radiological assessment. For recipients with Complete remission reported in question 85, this This date may match the date CR was achieved reported in question 87 for recipients with lymphomas, solid tumors, or other diseases with imaging criteria for reporting CR.
5/19/2022 2450: Post-TED Modify Instructions clarified on when to report no and yes for Q98: Report No if karyotyping studies were not performed during the reporting period positive for disease in the past but not performed during the current reporting period.
If the recipient’s best response is Not in Complete Remission, report the latest assessment performed during the reporting period and prior to treatment for relapsed, progressive, or persistent disease (excluding treatment for minimal residual disease). If testing was not performed prior to the initiation of treatment, report No and go to question 101 Yes if assessments were performed, prior to any relapse, progression or treatment for persistent disease, (excluding treatment for minimal residual disease). Report No if assessments were not performed, prior to any relapse, progression, or treatment for persistent disease (excluding treatment for minimal residual disease).
If the recipient’ best response is Complete Remission, report testing performed closest to the date of best response (question 87) and within the time windows in the Disease Assessment Time Windows table. If testing was not performed within the applicable time window, report No and go to question 101. Yes if disease assessments were performed within the time windows in the Disease Assessments Time Windows table above. If testing was not performed within the applicable time window, report No.
5/19/2022 2450: Post-TED Modify Instructions clarified on how to report the assessment date for Q99: If the best response is Complete remission, report the date of testing performed nearest the date of best response within the time window and prior to relapse or progression, if applicable. If the best response is Not in complete remission, report the date of the most recent karyotype testing performed during the reporting period and prior to treatment for relapsed, progressive, or persistent disease, if applicable. If no treatment for relapsed, progressive, or persistent disease was given, report the date of the most recent karyotype assessment performed within approximately 30 days of the follow-up date. any relapse, progression or treatment for persistent disease, if applicable.
5/19/2022 2450: Post-TED Add Instructions clarified on how to report yes for Q100: Report whether the recipient’s primary disease was detected by karyotyping on the date reported in question 100. Do not include clinically insignificant polymorphism, or chromosomal abnormalities of no known significance, as disease detected; this includes anomalies such as age-dependent loss of the chromosome Y This question may be reported as Yes even when Not in complete remission – no disease detected but incomplete evaluation to establish CR is reported as the best response.
5/19/2022 2450: Post-TED Add Instructions clarified on how to report yes for Q97: Report whether the recipient’s primary disease was detected by FISH testing on the date reported in question 96 This question may be reported as Yes even when Not in complete remission – no disease detected but incomplete evaluation to establish CR is reported as the best response.
5/19/2022 2450: Post-TED Modify Instructions clarified on how to report the assessment date for Q96: If the best response is Complete remission, report the date of testing performed nearest the date of best response within the time window and prior to relapse or progression, if applicable. If the best response is Not in complete remission, report the date of the most recent FISH testing performed during the reporting period and prior to treatment for relapsed, progressive, or persistent disease, if applicable. If no treatment for relapsed, progressive, or persistent disease was given, report the date of the most recent FISH performed within approximately 30 days of the follow-up date. any relapse, progression or treatment for persistent disease, if applicable.
5/19/2022 2450: Post-TED Modify Instructions clarified on when to report no and yes for Q95: Report No if FISH studies were not performed during the reporting period positive for disease in the past but not performed during the current reporting period.
If the recipient’s best response is Not in Complete Remission, report the latest assessment performed during the reporting period and prior to treatment for relapsed, progressive, or persistent disease (excluding treatment for minimal residual disease). If testing was not performed prior to the initiation of treatment, report No and go to question 98 Yes if assessments were performed, prior to any relapse, progression or treatment for persistent disease, (excluding treatment for minimal residual disease). Report No if assessments were not performed, prior to any relapse, progression, or treatment for persistent disease (excluding treatment for minimal residual disease).
If the recipient’ best response is Complete Remission, report testing performed closest to the date of best response (question 87) and within the time windows in the Disease Assessment Time Windows table. If testing was not performed within the applicable time window, report No and go to question 98. Yes if disease assessments were performed within the time windows in the Disease Assessments Time Windows table above. If testing was not performed within the applicable time window, report No.
5/19/2022 2450: Post-TED Modify Instructions clarified on when to report no and yes for Q94: Report No if cytogenetic studies were not performed during the reporting period positive for disease in the past but not performed during the current reporting period.
If the recipient’s best response is Not in Complete Remission, report the latest assessment performed during the reporting period and prior to treatment for relapsed, progressive, or persistent disease (excluding treatment for minimal residual disease). If testing was not performed prior to the initiation of treatment, report No and go to question 101 Yes if assessments were performed, prior to any relapse, progression or treatment for persistent disease, (excluding treatment for minimal residual disease). Report No if assessments were not performed, prior to any relapse, progression, or treatment for persistent disease (excluding treatment for minimal residual disease).
If the recipient’ best response is Complete Remission, report testing performed closest to the date of best response (question 87) and within the time windows in the Disease Assessment Time Windows table. If testing was not performed within the applicable time window, report No and go to question 101. Yes if disease assessments were performed within the time windows in the Disease Assessments Time Windows table above. If testing was not performed within the applicable time window, report No.
5/19/2022 2450: Post-TED Add Instructions clarified on how to report yes for Q93: Report whether the recipient’s primary disease was detected by flow cytometry on the date reported in question 93. Report Yes if an abnormal cell population associated with the recipient’s primary transplant disease was detected regardless of the sensitivity of the flow cytometry panel performed; this means an abnormal cell population detected by MRD flow cytometry would be reported in the same way as an abnormal cell population detected by a standard flow cytometry assay. This question may be reported as Yes even when Not in complete remission – no disease detected but incomplete evaluation to establish CR is reported as the best response.
5/19/2022 2450: Post-TED Modify Instructions clarified on how to report the assessment date for Q92: If the best response is Complete remission, report the date of testing performed nearest the date of best response within the time window and prior to relapse or progression, if applicable. If the best response is Not in complete remission, report the date of the most recent flow cytometry testing performed during the reporting period and prior to treatment for relapsed, progressive, or persistent disease, if applicable. If no treatment for relapsed, progressive, or persistent disease was given, report the date of the most recent flow cytometry assessment performed within approximately 30 days of the follow-up date. any relapse, progression or treatment for persistent disease, if applicable.
5/19/2022 2450: Post-TED Modify Instructions clarified on when to report no and yes for Q91: Report No if flow cytometry was not performed during the reporting period studies were positive for disease in the past but not performed during the current reporting period.
If the recipient’s best response is Not in Complete Remission, report the latest assessment performed during the reporting period and prior to treatment for relapsed, progressive, or persistent disease (excluding treatment for minimal residual disease). If testing was not performed prior to the initiation of treatment, report No and go to question 94 Yes if assessments were performed, prior to any relapse, progression or treatment for persistent disease, (excluding treatment for minimal residual disease). Report No if assessments were not performed, prior to any relapse, progression, or treatment for persistent disease (excluding treatment for minimal residual disease).
If the recipient’ best response is Complete Remission, report testing performed closest to the date of best response (question 88) and within the time windows in the Disease Assessment Time Windows table. If testing was not performed within the applicable time window, report No and go to question 94. Yes if disease assessments were performed within the time windows in the Disease Assessments Time Windows table above. If testing was not performed within the applicable time window, report No.
5/19/2022 2450: Post-TED Add Instructions clarified on how to report yes for Q90: Report whether the recipient’s primary disease was detected by molecular testing on the date reported in question 89. This question may be reported as Yes even when Not in complete remission – no disease detected but incomplete evaluation to establish CR is reported as the best response. In order to be considered positive for disease, the assay must detect a number of copies of the molecular marker exceeding the threshold for sensitivity of the assay, for a quantitative study. However, do note that presence of only a single marker among numerous tested is sufficient to indicate disease detected.
5/19/2022 2450: Post-TED Modify Instructions clarified on how to report the assessment date for Q89: If the best response is Complete remission, report the date of testing performed nearest the date of best response within the time window and prior to relapse or progression, if applicable. If the best response is Not in complete remission, report the date of the most recent molecular testing performed during the reporting period and prior to treatment for relapsed, progressive, or persistent disease, if applicable. If no treatment for relapsed, progressive, or persistent disease was given, report the date of the most recent molecular assessment performed within approximately 30 days of the follow-up date. any relapse, progression or treatment for persistent disease, if applicable.
5/19/2022 2450: Post-TED Modify Instructions clarified on when to report no and yes for Q88: Report No if molecular studies were not performed during the reporting period positive for disease in the past but not performed during the current reporting period.
If the recipient’s best response is Not in Complete Remission, report the latest assessment performed during the reporting period and prior to treatment for relapsed, progressive, or persistent disease (excluding treatment for minimal residual disease). If testing was not performed prior to the initiation of treatment, report No and go to question 91. Yes if assessments were performed, prior to any relapse, progression or treatment for persistent disease, (excluding treatment for minimal residual disease). Report No if assessments were not performed, prior to any relapse, progression, or treatment for persistent disease (excluding treatment for minimal residual disease).
If the recipient’ best response is Complete Remission, report testing performed closest to the date of best response (question 87) and within the time windows in the Disease Assessment Time Windows table. If testing was not performed within the applicable time window, report No and go to question 91. Yes if disease assessments were performed within the time windows in the Disease Assessments Time Windows table above. If testing was not performed within the applicable time window, report No.
5/19/2022 2450: Post-TED Modify Clarification added on when to select Disease detected for question 85: If disease persists by any radiological or clinical / hematological assessment indicate Disease detected. Persistence of abnormalities by molecular, cytogenetic, or flow cytometry assessments does not constitute “disease detected” and should not be reported as ‘disease detected’ for this question. Indicate Disease detected if disease persists by any method of radiological or clinical assessment; persistence of abnormalities by molecular, cytogenetic, or flow cytometry assessments does not constitute “disease detected.”
5/18/2022 2450: Post-TED Add The Combined Follow Up blue instruction box were added to questions 14, 17, 50, 57, 84, 107, 112, 115, and 123 for clarification on when these questions will come due.
5/6/2022 2450: Post-TED Modify Clarified instructions on how to report the best response for tandem transplants: Tandem Transplants: For recipients receiving a tandem transplant, the best response to the prior transplant (i.e., HCT #1 of the tandem) depends on the pre-transplant disease status.
  • If the recipient was in complete remission at the time of HCT #1 or achieved complete remission prior to HCT #2 of their tandem transplant, report the best response to transplant as Continued complete remission (CCR)
  • If the recipient was not in complete remission or did not achieve complete remission in response to HCT #1 prior to HCT #2 of their tandem transplant, either “Not in complete remission (NCR)” or “Not evaluated” would be appropriate options, however, ensure the best response to transplant and the current diseases status are answered consistently
  • If the recipient was not in complete remission at the time of HCT #1, and no disease assessments (including labs and / or physician’s exams) occurred in the reporting period, between HCT #1 and HCT #2 of their tandem transplant, report Not evaluated. However, ensure the best response to transplant and the current disease status are reported consistently
  • If the recipient was not in complete remission at the time of HCT #1, and achieved complete remission prior to HCT #2 of their tandem transplant, report Complete remission, the date which a complete remission was achieved
  • If the recipient was not in complete remission at the time of HCT #1 and did not achieve complete remission in response to HCT #1 and prior to HCT #2 of their tandem transplant, report Not in complete remission (NCR)
4/8/2022 2450: Post-TED Add Clarification added on when to report a COVID-19 infection:Possible Reporting Scenarios: An infection should be reported if: A recipient has a positive antibody result. They do not have a history of positive COVID diagnostic results (PCR or antigen); The recipient was symptomatic and treated, but COVID-19 diagnostic testing was not performed and / or COVID diagnostic testing was performed and negative. An infection should not be reported if: A recipient has a positive COVID diagnostic result (PCR or antigen). No treatment was given and/or recipient was asymptomatic.
4/8/2022 2450: Post-TED Add COVID-19 Reinfection blue box added in Q50 – 51: Reporting COVID-19 Reinfection There have been cases of recipients recovering from COVID-19 infection, only to later test positive again. For CIBMTR purposes, a new COVID-19 infection should be reported when a recipient tests positive again >21 days from resolution (resolution defined as no signs or symptoms of infection, or a negative diagnostic test).
4/8/2022 2450: Post-TED Add Clarification added in regard to revaccination post-infusion: Indicate if the recipient received a vaccine for COVID-19 (one dose without a planned second dose, first dose with planned second dose, second dose, third dose, and / or booster dose) within the current reporting period. If the recipient did not receive a vaccine for COVID-19 or it is not known if the recipient received a vaccine, select No or Unknown, respectively, and continue with question 57. Revaccination Post-Infusion: When vaccines are given post-infusion, the physician should make the determination on whether the doses are part of the primary series of vaccines, third primary dose, boosters, or revaccination. If a recipient receives a new course of COVID vaccines following infusion as revaccination, report the vaccines as a new series. The most up to date CDC COVID-19 vaccine information for immunocompromised people can be found here.
4/8/2022 2450: Post-TED Add Clarification added on what to report if vaccine brand is Unknown: For the reported dose, specify the vaccine brand the recipient received. If the vaccine brand is not listed, select Other type and specify in question 92. If the vaccine brand is unknown, leave the field blank and override the error as Unknown.
4/7/2022 2450: Post-TED Add Third dose versus Booster dose blue box added above question 55 – 56 for clarification: Third dose versus Booster dose: To determine between a third dose and a booster dose, seek clinician clarification, as needed, using the guidelines listed below:
Third dose: An additional primary dose required for recipients who did not build enough protection from their primary vaccine series, typically for immunocompromised individuals
Booster dose: Administered to recipients who have enough protection after completing their primary vaccine series but then protection decreases over time
Primary vaccine series: Two doses of Pfizer-BioNTech or Moderna; One dose of Johnson & Johnson’s Janssen.
3/24/2022 2450: Post-TED Add COVID-19 Vaccine blue box added above question 52: COVID-19 Vaccine: If the recipient received a COVID-19 vaccine at any time (including pre- or post-infusion) prior to October 2021 (before the COVID-19 vaccine questions were available on the Post-TED (2450) form), select Yes for question 52 at the first opportunity this form becomes available. When reporting the vaccine date, report the actual date the recipient received the vaccine, even if the date is outside of the reporting window or prior to infusion, override the error as Verified Correct and specify in the comments “Per CIBMTR instructions, report actual vaccine date and verify data field as correct.”
1/25/2022 2450: Post-TED Modify Update question numbers to match with form.
1/25/2022 Chimerism Studies Modify Update question numbers to match with form.
1/25/2022 Disease Assessment at the Time of Best Response to HCT Modify Update question numbers to match with form.
1/25/2022 Post-HCT Therapy Modify Update question numbers to match with form.
1/25/2022 Relapse or Progression Post-HCT Modify Update question numbers to match with form.
1/25/2022 Current Disease Status Modify Update question numbers to match with form.
10/29/2021 2450: Post-TED Modify Version 5 of the 2450: Post-TED section of the Forms Instruction Manual released. Version 5 corresponds to revision 6 of the Form 2450.
Last modified: May 19, 2022

Need more help with this?
Don’t hesitate to contact us here.

Was this helpful?

Yes No
You indicated this topic was not helpful to you ...
Could you please leave a comment telling us why? Thank you!
Thanks for your feedback.